Actively Recruiting
Peri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia
Led by John Sapp · Updated on 2026-03-17
20
Participants Needed
1
Research Sites
386 weeks
Total Duration
On this page
Sponsors
J
John Sapp
Lead Sponsor
N
Nova Scotia Health Authority
Collaborating Sponsor
AI-Summary
What this Trial Is About
Ventricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical "short circuit" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. An important treatment is to use catheter ablation to "block" the channel that forms the circuit. Effective ablation requires imaging guidance to visualize the VT circuit relative to scar structures in 3D. Unfortunately, with conventional catheter mapping, up to 90% of the VT circuits are too short-lived to be mapped. For the 10% "mappable" VTs, their data are only available during ablation and limited to one ventricular surface. This inadequacy of functional VT data largely limits the knowledge about scar-related VT and ablation strategies, and reduces the ability of clinicians to identify ablation targets and assess ablation outcome. The central hypothesis of this proposal is that functional VT data, integrated with CT or MRI scar data in 3D, can improve VT ablation efficacy with pre-procedural identification of ablation targets and post-procedural mechanistic elucidation of ablation failure. This research builds on the rapidly increasing clinical interest in electrocardiographic imaging (ECGi), an emerging technique that obtains cardiac electrical activity through inverse reconstructions from ECGs. The specific objective is to push the boundary of ECGi to provide - as a conjunction to intra-procedural catheter mapping - pre-ablation and post-ablation imaging of functional VT circuits integrated with 3D scar structure.
CONDITIONS
Official Title
Peri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- One or more episodes of sustained monomorphic ventricular tachycardia
- Referred for catheter ablation
- Previously implanted implantable cardioverter defibrillator (ICD)
- Signed the patient informed consent form
- Able and willing to comply with all pre-, post-, and follow-up testing and requirements
You will not qualify if you...
- Estimated Glomerular Filtration Ratio (eGFR) less than 30
- Life expectancy less than 6 months or listed for heart transplantation at time of inclusion
- Pregnant
- Receiving intravenous inotropic agents
- Any contraindication to catheter ablation, including mechanical prosthetic aortic and mitral valves or known protruding left ventricular thrombus
- New York Heart Association (NYHA) functional class IV
- Had ST wave elevation myocardial infarction within less than 1 month
- Unwilling or unable to undergo cardiac MRI scan and unwilling or unable to undergo cardiac CT scan (e.g., contrast allergy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
QEII HSC
Halifax, Nova Scotia, Canada, B3H 3A7
Actively Recruiting
Research Team
J
John L Sapp, MD FRCPC
CONTACT
K
Karen A Giddens
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here